Skip to the answer

Pacritinib

Pacritinib is a targeted kinase inhibitor used to treat intermediate or high-risk myelofibrosis (a bone marrow disorder) in adults with very low platelet counts.

Brand name Vonjo
Drug class Kinase Inhibitor
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Pacritinib at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Pacritinib (Vonjo) is a specialist medicine that blocks JAK2 and related signaling proteins to treat intermediate or high-risk myelofibrosis, a scarring bone marrow disease; on the market since about 2022, it is mainly for adults whose platelets are too low for the more familiar JAK inhibitors. Most people tolerate it fairly well; diarrhea is what they notice most, plus nausea and swollen legs or feet. Watch above all for bleeding, which has been serious and even fatal; report unusual bruising or blood in stool or urine right away. Heart attack, stroke, blood clots and heart rhythm changes can also occur, so expect regular blood counts and heart checks.

Clinical pearls

  • Tell every surgeon and dentist you take it, since it must be stopped at least 7 days before planned procedures.
  • Hormonal birth control may work less well, so use an IUD or add a nonhormonal method until 30 days after stopping.
  • Itraconazole, rifampin and some seizure medicines are off-limits with it, so have every new antibiotic or antifungal checked first.
  • Never stop it on your own, because myelofibrosis symptoms can flare quickly once doses are interrupted.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asCapsule
Earliest FDA record2022
Companies listing it with the FDA1
FDA label last updatedJul 30, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Pacritinib, written from its FDA label.

What Pacritinib is used for

▾

Pacritinib is used to treat a serious bone marrow condition called myelofibrosis in adult patients with very low platelet counts.

  • Vonjo is indicated for adults with intermediate or high-risk primary myelofibrosis (MF) who have a platelet count below 50 × 10⁹/L
  • Vonjo is also indicated for secondary MF — specifically post-polycythemia vera MF and post-essential thrombocythemia MF — with the same very low platelet count threshold
  • This approval is based on demonstrated reductions in spleen volume and is granted under accelerated approval; continued approval may depend on confirmatory trial results

How Pacritinib works

▾

Pacritinib is a kinase inhibitor — meaning it blocks specific proteins that act as on/off switches for cell growth and inflammation. It targets JAK2 (including the mutated JAK2V617F form found in many MF patients), FLT3, IRAK1, and ACVR1/ALK2. In myelofibrosis, JAK2 signaling is dysregulated (out of control), driving abnormal blood cell production and spleen enlargement. By blocking these kinases, pacritinib helps interrupt those overactive signals. Notably, pacritinib does not significantly inhibit JAK1 at therapeutic levels, and it has stronger activity against JAK2 than against JAK3 or TYK2.

Pacritinib dosage

▾

Vonjo is taken as oral capsules twice a day, with or without food — there is no need to time it around meals. Capsules should be swallowed whole; do not open, break, or chew them. If a dose is missed, skip it and take the next scheduled dose at the regular time — never take extra to compensate.

  • Patients with severe liver disease (Child-Pugh C) start at a lower dose, with possible increase after 12 weeks if needed and tolerated
  • If switching from another kinase inhibitor, your prescriber will guide you on tapering that drug first
  • Vonjo should be stopped at least 7 days before any planned surgery or invasive procedure

Dosing details from the FDA-approved label

From the Pacritinib prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Recommended dosage (adults)
    • 200 mg orally twice daily
    • May be taken with or without food
    • Swallow capsules whole
    • Do not open, break, or chew capsules
  • Dose reduction levels for adverse reactions
    • 200 mg twice daily (initial starting dose), 100 mg twice daily (first dose reduction), 100 mg once daily (second dose reduction)
    • Discontinue in patients unable to tolerate a dose of 100 mg daily
  • Severe hepatic impairment (Child-Pugh C)
    • 100 mg twice daily
    • May be increased to 200 mg twice daily if the treatment is not effective after 12 weeks and there are no safety concerns
    • Continue monitoring for safety
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Recommended dosage is 200 mg orally twice daily ( 2.1 ). May be taken with or without food ( 2.1 ). 2.1 Recommended Dosage The recommended dosage of VONJO is 200 mg orally twice daily. VONJO may be taken with or without food. Swallow capsules whole. Do not open, break, or chew capsules. Patients who are on treatment with other kinase inhibitors before the initiation of VONJO must taper or discontinue according to the prescribing information for that drug. 2.2 Monitoring for Safety Perform a complete blood count (CBC; including white blood cell count differential and platelet count), coagulation testing (prothrombin time, partial thromboplastin time, thrombin time, and international normalized ratio) and a baseline electrocardiogram (ECG), prior to starting VONJO, and monitor as clinically indicated while the patient is on treatment. 2.3 Missed Dose If a dose of VONJO is missed, the patient should take the next prescribed dose at its scheduled time. Extra capsules should not be taken to make up for the missed dose. 2.4 Dose Interruption for Planned Surgical Procedures or Other Interventions Discontinue VONJO 7 days prior to elective surgery or invasive procedures because of the risk of hemorrhage and restart only after hemostasis is assured. 2.5 Dose Modification for Adverse Reactions Dose modifications for diarrhea, thrombocytopenia, hemorrhage, and prolonged QT interval are described in Table 1 , Table 2 , Table 3 , and Table 4 respectively. See Warning and Precautions ( 5.1 , 5.2 , 5.3 , and 5.4 ) for additional risk minimization recommendations. Dose levels for VONJO are as follows: 200 mg twice daily (initial starting dose), 100 mg twice daily (first dose reduction), 100 mg once daily (second dose reduction). Discontinue VONJO in patients unable to tolerate a dose of 100 mg daily. Table 1 Dosage Modification for Diarrhea Toxicity Management/Action a Increase of at least 7 stools per day over baseline, or hospitalization indicated, or severe increase in ostomy output over baseline, or if limiting self-care. b Increase of <4 stools per day over baseline or mild increase in ostomy output compared to baseline. New onset of diarrhea Initiate anti-diarrheal medications. Encourage adequate oral hydration. Grade 3 or 4 a Hold VONJO until the diarrhea resolves to Grade 1 b or lower or baseline. Restart VONJO at the last given dose.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Pacritinib side effects

▾

The most common side effects reported in clinical trials (occurring in 20% or more of patients) include:

Common side effects

  • Diarrhea
  • Low platelet count (thrombocytopenia)
  • Nausea
  • Anemia (low red blood cells)
  • Peripheral edema (swelling in the legs or feet)
  • Diarrhea — the most frequently reported; can often be managed with anti-diarrheal medications or dose adjustments

When to get medical help

  • Call your doctor right away if you have unusual bleeding, bruising, or blood in your stool or urine — serious and even fatal bleeding has occurred
  • Seek urgent care for chest pain, shortness of breath, or signs of a heart attack or stroke (major adverse cardiac events)
  • Tell your doctor immediately if you develop signs of a blood clot: leg swelling, pain, redness, or sudden difficulty breathing
  • Report signs of infection — fever, chills, or feeling very unwell — since serious infections can occur
  • Contact your doctor if you notice new or worsening irregular heartbeat or feel dizzy or faint (QT interval prolongation risk)
  • Report any new lumps, unusual weight loss, or other signs that could suggest a secondary cancer
  • If you stop or interrupt treatment, watch for a rapid return or worsening of MF symptoms and contact your doctor

Pacritinib warnings and precautions

▾
  • Bleeding: Serious (11%) and fatal (2%) hemorrhages have occurred. Avoid Vonjo if you have active bleeding. Stop it 7 days before any surgery. Dose adjustments may be needed based on severity.
  • Major Adverse Cardiac Events (MACE): Heart attacks and other serious cardiac events may occur, especially in people who smoke or have other heart disease risk factors. Seek care immediately for chest pain or stroke symptoms.
  • Blood clots (thrombosis): Deep vein thrombosis, pulmonary embolism (clot in the lung), and arterial clots have been reported. Watch for leg swelling, pain, or sudden breathing difficulty.
  • QT prolongation: Vonjo can lengthen the QT interval (a heart rhythm measurement), which may cause dangerous arrhythmias. Vonjo should not be used if your baseline QTc exceeds 480 msec. Low potassium (hypokalemia) must be corrected before and during treatment.
  • Serious infections: Delay starting Vonjo until active serious infections are resolved. Report fever or signs of infection promptly.
  • Secondary malignancies: Cases of lymphoma and other cancers have been reported. Smokers and ex-smokers may be at higher risk.
  • Symptom flare on stopping: Abruptly stopping Vonjo can cause MF symptoms to worsen rapidly. Never stop without consulting your doctor.

Pacritinib interactions

▾

Vonjo has several important drug interactions that can affect either its safety or effectiveness, or the safety of other medications you take.

  • Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, certain HIV medications): Contraindicated — these raise pacritinib levels dangerously
  • Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine): Contraindicated — these lower pacritinib levels, reducing its effectiveness
  • Moderate CYP3A4 inhibitors (e.g., fluconazole up to 200 mg/day): Use with caution; your doctor may reduce your Vonjo dose
  • Digoxin: Vonjo raises digoxin blood levels — regular digoxin monitoring is required
  • Rosuvastatin: Vonjo raises rosuvastatin levels significantly — daily dose of rosuvastatin must not exceed 20 mg while on Vonjo
  • Hormonal contraceptives (pills, patches, rings, implants): Vonjo may make these less effective — use a levonorgestrel intrauterine system or nonhormonal backup contraception during treatment and for 30 days after your last dose
  • CYP1A2 substrates (e.g., certain antidepressants, theophylline): Vonjo raises their levels — watch for increased side effects
  • CYP2C19 and CYP3A4 substrates: Vonjo lowers their levels — these drugs may become less effective; dose adjustments may be needed

Interactions listed in the FDA-approved label

From the Pacritinib prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inhibitors: Increase pacritinib exposure, which may increase the risk of exposure-related adverse reactions. Co-administration is contraindicated.
  • Moderate CYP3A4 inhibitors (e.g., fluconazole): Increase pacritinib exposure, which may increase the risk of exposure-related adverse reactions. Monitor for increased adverse reactions and consider VONJO dose modifications based on safety. Use with fluconazole doses greater than 200 mg once daily has not been studied.
  • Strong CYP3A4 inducers: Decrease pacritinib exposure, which may reduce efficacy of VONJO. Co-administration is contraindicated.
  • CYP1A2 substrates: VONJO increases plasma concentrations of CYP1A2 substrates, which may increase the risk of adverse reactions from the substrate. Monitor for substrate-related adverse reactions more frequently, unless otherwise recommended in the substrate Prescribing Information, where minimal concentration changes may lead to serious adverse reactions.
  • CYP2C19 substrates: VONJO decreases plasma concentrations of CYP2C19 substrates, which may decrease the efficacy of the substrate. Monitor efficacy of the substrate more frequently, unless otherwise recommended in the substrate Prescribing Information; dose adjustment of the substrate may be needed.
  • CYP3A4 substrates: VONJO decreases plasma concentrations of CYP3A4 substrates, which may decrease the efficacy of the substrate. Monitor efficacy of the substrate more frequently, unless otherwise recommended in the substrate Prescribing Information; dose adjustment of the substrate may be needed.
  • Hormonal contraceptives: The effectiveness of hormonal contraceptives, except for intrauterine systems containing levonorgestrel, may be reduced when used with VONJO. Avoid concomitant use except for intrauterine systems containing levonorgestrel. If contraception is needed, use an alternate contraceptive not affected by CYP3A4 inducers (e.g., an intrauterine system) or additional nonhormonal contraceptive (e.g., condoms) during treatment and for 30 days after last dose.
  • P-gp substrates (including digoxin): VONJO increases plasma concentrations of P-gp substrates, which may increase the risk of adverse reactions from the substrate. Monitor for substrate-related adverse reactions more frequently, unless otherwise recommended in the substrate Prescribing Information. Digoxin: measure serum digoxin concentrations before initiating concomitant use and continue monitoring as recommended in the digoxin Prescribing Information.
  • BCRP substrates (including rosuvastatin): VONJO increases plasma concentrations of BCRP substrates, which may increase the risk of adverse reactions from the substrate. Monitor for substrate-related adverse reactions more frequently and consider dose reduction of the substrate according to its Prescribing Information. Rosuvastatin dose should not exceed 20 mg once daily when used with VONJO.
Read the label’s full interactions text

7 DRUG INTERACTIONS Co-administration of VONJO with moderate CYP3A4 inhibitors can increase the exposure to pacritinib. Monitor for increased adverse reactions of VONJO when administered with moderate CYP3A4 inhibitors ( 7.1 ). VONJO is an inhibitor of P-gp, BCRP, and CYP1A2 and an inducer of CYP3A4 and CYP2C19. Monitor patients concomitantly receiving substrates of these transporters and enzymes, and adjust dose of the substrates as needed ( 7.2 ). VONJO may reduce the effectiveness of hormonal contraceptives ( 7.2 ) 7.1 Effect of Other Drugs on VONJO Strong and Moderate CYP3A4 Inhibitors Pacritinib is predominantly metabolized by CYP3A4. Concomitant use of VONJO with strong and moderate CYP3A4 inhibitors increases pacritinib exposure, which may increase the risk of exposure-related adverse reactions [see Clinical Pharmacology ( 12.3 )] Co-administration of VONJO with strong CYP3A4 inhibitors is contraindicated [see Contraindications ( 4 )]. Monitor patients concomitantly receiving moderate CYP3A4 inhibitors (e.g., fluconazole) for increased adverse reactions and consider VONJO dose modifications based on safety [see Dosage and Administration ( 2.5 )] . Concomitant use of VONJO with doses of fluconazole greater than 200 mg once daily has not been studied. Strong CYP3A4 Inducers Pacritinib is predominantly metabolized by CYP3A4. Concomitant use of VONJO with strong CYP3A4 inducers decreases pacritinib exposure, which may reduce efficacy of VONJO [see Clinical Pharmacology ( 12.3 )] . Co-administration of VONJO with strong CYP3A4 inducers is contraindicated [see Contraindications ( 4 )]. 7.2 Effect of VONJO on Other Drugs CYP1A2 Substrates Pacritinib is an inhibitor of CYP1A2. VONJO increases the plasma concentrations of CYP1A2 substrates [see Clinical Pharmacology ( 12.3 )] ,which may increase the risk of adverse reactions from the CYP1A2 substrate.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿158 supplements and herbs with documented Pacritinib interactions, ranked by severity Check Pacritinib against a supplement or herb →

Before taking Pacritinib

▾
  • Tell your doctor if you have active bleeding or very low platelets beyond what MF already causes — Vonjo may not be safe to start
  • Tell your doctor if you have a prolonged QT interval on ECG (above 480 msec) — Vonjo is not appropriate in this case
  • Tell your doctor if you have low potassium levels (hypokalemia) — this must be corrected before starting
  • Tell your doctor if you have severe liver disease (Child-Pugh C) — a reduced starting dose is required
  • Tell your doctor if you have very poor kidney function (eGFR below 15 mL/min) or are on dialysis — use is not recommended
  • Do not breastfeed while taking Vonjo
  • If you currently or formerly smoke, tell your doctor — this may increase your risk of heart events and secondary cancers on this medication
  • If you are planning surgery or an invasive procedure, alert your care team — Vonjo must be stopped 7 days beforehand
  • Tell your doctor about all medications you take, including over-the-counter drugs, supplements, and contraceptives, due to the many potential interactions

Pacritinib overdose

▾

Taking too much Vonjo can cause gastrointestinal problems (nausea, diarrhea), dangerously low blood counts (myelosuppression), blurred vision, dizziness, worsening overall condition, and serious infections such as sepsis. There is no specific antidote for a Vonjo overdose, and hemodialysis (a kidney filtration procedure) is not expected to remove the drug from the body effectively. If you think you or someone else has taken too much, seek emergency medical care immediately.

What Pacritinib does in the body

▾

Pacritinib blocks the phosphorylation (activation) of signaling proteins called STAT5 and STAT3 — key steps in the abnormal cell-signaling chain that drives myelofibrosis. These effects have been demonstrated in laboratory and early clinical studies. Vonjo has also been shown to affect heart electrical conduction: in a 24-week study of MF patients, it produced a mean increase in the QTcF interval (a standardized heart rhythm measurement) of about 11 milliseconds, which is why cardiac monitoring is required during treatment.

How your body processes Pacritinib

▾

After taking Vonjo by mouth, pacritinib reaches peak blood levels in about 4 to 5 hours, and its levels build up (accumulate) significantly with twice-daily dosing, reaching a steady state within about one week. It is heavily bound to proteins in the blood (about 99%) and is broken down primarily by an enzyme called CYP3A4 in the liver. The drug is eliminated mostly through the feces (about 87%), with very little leaving through urine (about 6%). Its effective half-life — the time it takes for blood levels to drop by half — is roughly 28 hours. Patients with severe liver disease have higher drug exposure, while those with moderately reduced kidney function (eGFR 15–29 mL/min) show about a 30% increase in exposure; very poor kidney function or dialysis is not recommended.

How to store Pacritinib

▾

Store at room temperature, below 30°C (86°F). protect from light. Store in original package.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

158

Supplements & herbs that interact with Pacritinib

158 supplements and herbal products have documented interactions with Pacritinib in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 8
  • Moderate · 110
  • Minor · 40
ACTIVATED CHARCOAL Major AMERICAN HELLEBORE Major ARSENIC Major CESIUM Major EPHEDRA Major GRAPEFRUIT Major SIDA CORDIFOLIA Major ST. JOHN'S WORT Major +150 more
Every supplement checked against Pacritinib — ranked by severity The full interaction hub: 8 major · 110 moderate · 40 minor · every one linked to its full report. Check Pacritinib against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Pacritinib: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Pacritinib — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is Vonjo used for, and why was it prescribed for me?

▾
Vonjo is used to treat a bone marrow disease called myelofibrosis — either the primary kind or a type that develops after another blood disorder. What makes it unique is that it's specifically approved for patients like you who have very low platelet counts, a situation where many other treatments aren't safe or appropriate. It works by shrinking an enlarged spleen and targeting the out-of-control signaling that drives the disease.

How do I take this medication, and does it matter if I take it with food?

▾
You take Vonjo capsules twice a day — and the good news is you can take it with or without food, whichever is easier for you. Just swallow the capsules whole; don't open, crush, or chew them. If you miss a dose, skip it and take your next one at the regular time — don't double up to make up for it.

What side effects should I expect, and which ones mean I should call right away?

▾
The most common things people notice are diarrhea, nausea, swelling in the legs or feet, and low blood counts (which your doctor will monitor with regular blood tests). Those are manageable, and your team can help. But call your doctor right away — or go to the emergency room — if you have unusual or heavy bleeding, chest pain, sudden shortness of breath, signs of a blood clot, fever or chills, or feel suddenly much worse. These can be signs of serious complications that need prompt attention.

Are there any medications I need to avoid while I'm on Vonjo?

▾
Yes, there are some important ones. Certain antifungals, antibiotics, and other drugs that strongly affect a liver enzyme called CYP3A4 are actually contraindicated — meaning you cannot take them with Vonjo. Vonjo can also raise the levels of drugs like digoxin and rosuvastatin (a cholesterol medication), so those may need dose adjustments. Make sure every doctor and pharmacist you see knows you're on Vonjo before they prescribe or recommend anything new.

I use hormonal birth control — is that okay to continue?

▾
This is really important to know: Vonjo can make most hormonal contraceptives — like the pill, patch, or ring — less effective at preventing pregnancy. During treatment and for 30 days after your last dose, you should use either a levonorgestrel intrauterine system (a hormonal IUD) or a nonhormonal backup method like condoms. Talk with your doctor or pharmacist about the best option for you.

Is it safe to stop taking Vonjo on my own if I feel bad or want a break?

▾
Please don't stop Vonjo without talking to your doctor first. When this medication is stopped or interrupted — even briefly — myelofibrosis symptoms can come back hard and fast. Your doctor can help you manage side effects, adjust the dose if needed, or plan a safe interruption if you have surgery or another procedure coming up. Always reach out before making any changes.

Is Pacritinib available over the counter?

▾
No. Pacritinib is a prescription medicine: every Pacritinib product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Pacritinib first available?

▾
The earliest FDA record we hold for Pacritinib is from 2022: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Pacritinib was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Pacritinib on HelloPharmacist

📊Pacritinib supplement interactions158 checked — ranked by severity 🌿Drug & Supplement CheckerPacritinib vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Pacritinib NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Pacritinib Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Pacritinib forms and strengths (how it comes)

Pacritinib is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Capsule

By mouth
Brands Vonjo
How this form is used
What it may be used for
  • Vonjo capsules are used to treat adults with intermediate or high-risk primary or secondary myelofibrosis with a platelet count below 50 × 10⁹/L
  • Vonjo is approved under accelerated approval based on spleen volume reduction in this patient population
Important instructions
  • Vonjo capsules are taken by mouth twice daily, with or without food
  • Swallow Vonjo capsules whole — do not open, break, or chew them
  • If you miss a dose of Vonjo, take your next dose at the scheduled time; do not double up
  • Vonjo must be stopped 7 days before any planned surgery or invasive procedure
Available strengths 1 strength
100 mg
4 FDA-listed product records ⓘ

Pacritinib on the U.S. market: products, makers and brands

How Pacritinib appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 1 Pacritinib product record with the FDA, mostly as capsule; the earliest marketing or approval year on record is 2022. Brand names on the directory include Vonjo; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names
1
FDA-listed product records ⓘ
2022
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (1) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

How widely Pacritinib is used (Medicaid data)

A general measure of how commonly Pacritinib is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Pacritinib is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

13
Medicaid prescriptions filled (Q1–Q4 2025)
$336,585 gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Pacritinib prescribed? Of the 1,601 medications we measure, Pacritinib ranks #1,584 by Medicaid prescriptions — more than 1% of them.

Where Pacritinib ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,584 of 1,601
#1,579 Mosunetuzumab-axgb Inj... 15 Rx #1,580 Acetaminophen / Ibupro... 15 Rx #1,581 Hyaluronidase / Ocreli... 15 Rx #1,582 Artemether and Lumefan... 14 Rx #1,583 Phenoxybenzamine 14 Rx #1,584 Siltuximab Injection 13 Rx #1,585 Phenytoin Injection 13 Rx #1,586 Dactinomycin 13 Rx #1,587 Tetrahydrozoline Ophth... 13 Rx #1,588 Papaverine 13 Rx #1,589 Pacritinib 13 Rx

Utilization by Pacritinib product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

pacritinib 100 MG Oral Capsule

13 Medicaid prescriptions (Q1–Q4 2025) 100% of Pacritinib prescriptions shown $336,585 gross reimbursement (before rebates) ≈ $25,891 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2595248

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Pacritinib, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 1 listed Pacritinib NDCs with Medicaid activity.

Compare Pacritinib products

A representative set of FDA-listed product records for Pacritinib — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Capsule
100 mg Oral Sobi, Inc. NDA View NDC →

Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Pacritinib NDCs →

Pacritinib recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Pacritinib recalls since July 2021.

✅No Pacritinib recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Pacritinib RxCUI 2595243 1 dose form · 1 strength
  1. Dose form (SCDF) Oral Capsule RxCUI 2595247 In current FDA listings
    Clinical drug / strength (SCD) 100 MG RxCUI 2595248

Look up RxCUI 2595243 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Pacritinib brand names

Pacritinib is sold under one brand name in the FDA directory — Vonjo. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Vonjo

Who makes Pacritinib: manufacturers and labelers

One company lists Pacritinib products with the FDA. By number of product records, the largest are Sobi, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Sobi, Inc. 1

Pacritinib drug class (RxNorm)

Pacritinib belongs to the Kinase Inhibitor class.

Pharmacologic class Kinase Inhibitor
Drug family (ATC) Janus-associated kinase (JAK) inhibitors
How it works Tyrosine Kinase Inhibitors, Cytochrome P450 1A2 Inhibitors, Cytochrome P450 3A4 Inhibitors, P-Glycoprotein Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Pacritinib page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jul 30, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Pacritinib.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Pacritinib after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Finished products in the current FDA directory
1
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Sobi, Inc.
Linked label effective
Jul 30, 2026
Composite sections available
22
Linked SPL Set ID
4b5ab444-0e1a-4984-99db-76ad11a298ee
Linked SPL Document ID
eaca3a36-2256-47c8-ae49-3a866c61a133
Open the linked representative label on DailyMed ↗
NDC package records associated with this linked SPL 1

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Sobi, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →